TC BioPharm's Special Dividend Announcement
On a recent Wednesday, TC BioPharm (Holdings) PLC (NASDAQ: TCBP) made headlines with the announcement that its Board of Directors has approved a special dividend. This dividend will amount to 0.25 American Depositary Shares for each 1 ADS held by its investors, pending necessary shareholder approval.
Details of the Announcement
The company has decided to schedule a general meeting where the shareholders will have the opportunity to participate in discussions about this special dividend proposal. This meeting is planned for a date at the end of December.
Dividend Declaration and Payment Schedule
Shareholders of TC BioPharm can expect the dividend to be officially declared on a day in late December and it will be payable to those individuals who hold the company's shares as of the closing of trading on the first business day of January.
CEO's Insights on the Special Dividend
CEO Bryan Kobel expressed his enthusiasm regarding the announcement, stating, "We are extremely pleased to announce this special dividend, as our shareholders have shown remarkable support during a challenging capital markets landscape. This support came during a time when the company faced substantial pressures, including being targeted by unfounded campaigns aimed at misleading the market."
Focus on Innovative Cancer Therapies
TC BioPharm specializes in developing cutting-edge biopharmaceuticals, particularly around gamma-delta T-cell therapy aimed at treating cancer. Their research is backed by human efficacy data specifically targeting acute myeloid leukemia, showcasing their commitment to advancing healthcare solutions.
Understanding Gamma-Delta T Cells
Gamma-delta T cells are unique immune cells recognized for their dual characteristics that bridge innate and adaptive immunity. These cells possess an inherent capability to discern between healthy and diseased tissues effectively.
Clinical Trials Underway
The organization is currently conducting two pivotal clinical trials led by investigators for its gamma-delta T cell therapy products. They are focused on a critical Phase 2b/3 trial which studies the efficacy of their proprietary allogeneic CryoTC technology in treating acute myeloid leukemia. This technology facilitates the delivery of frozen products to clinics globally, ensuring patients have access to innovative treatment options.
Market Performance Insights
As of the latest session on Wednesday, shares of TCBP were noted to be trading at a price of $0.46, reflecting a decrease of 1.94% during the premarket trading hours. This modest fluctuation indicates the active interest and movement reflecting investor sentiment around the company’s recent announcements.
Frequently Asked Questions
What is the special dividend amount announced by TC BioPharm?
TC BioPharm has announced a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders.
When will the special dividend be declared?
The special dividend is expected to be declared on a date at the end of December.
Who is eligible for the special dividend?
Only shareholders who own TC BioPharm stock at the close of trading on a specific date in January will be eligible for the special dividend payment.
What are gamma-delta T cells?
Gamma-delta T cells are immune cells that play a crucial role in identifying and differentiating between healthy and diseased tissues, making them key players in cancer treatment.
What type of trials is TC BioPharm conducting?
TC BioPharm is conducting two investigator-initiated clinical trials focused on their gamma-delta T cell product line, including a pivotal trial for acute myeloid leukemia.
